Clinical trial
Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult…
NCT00302016 · Novartis Pharmaceuticals, Industry · No longer available
Key facts
| NCT number | NCT00302016 |
|---|---|
| Title | Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia |
| Official title | An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase. |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | No longer available |
| Study type | Expanded Access |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | AMN107 |
| Start date | Jan 1, 2006 |
| Primary completion | Nov 1, 2008 |
| First posted | Mar 13, 2006 |
| Last update posted | Aug 26, 2011 |
| Countries | Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hong Kong and 22 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: